

July, 2016 - In This Issue:




COMPARATIVE BIOSCIENCES, INC.

SHAPING OCULAR RESEARCH

DIABETIC RETINOPATHY

STREPTOZOTOCIN-INDUCED DIABETES




TOGETHER. SHAPING OCULAR RESEARCH.

CBI has demonstrated expertise in all phases of the in vivo drug discovery & development process related to nonclinical ocular projects. Our highly specialized staff are experienced in providing exploratory/proof-of-concept studies, developing specialized in vivo animal models, pharmacology and pharmacokinetic studies, as well as GLP toxicology / safety assessment programs. Specialty areas include ocular histopathology & immunohistochemistry of the eye, as well as [Optical Coherence Tomography \(OCT\)](#) and Electroretinogram (ERG) assessments in rodents and large animals. CBI is committed and has a dedicated track record of providing ophthalmology research services to pharmaceutical, biotech, and medical device companies. For specialized ocular research, think CBI.

[Learn More About CBI's Ocular Capabilities](#)

DIABETIC RETINOPATHY

Diabetic Retinopathy affects blood vessels in the light-sensitive tissue of the retina, and is the most common cause of vision loss among diabetics. This condition is characterized by microvascular changes that include leakage, increased neovascularity, increased tortuosity, as well as neutrophil attachment and leukostasis. Largely still an uncured medical condition, CBI has been helping our Sponsors push through this and other developing ocular therapies for 20 years. CBI's experience and our Sponsors' innovations are leading to new therapies and clinical trials to advance treatment of ocular diseases.



[View Our Other Ocular Models Here](#)

STREPTOZOTOCIN-INDUCED DIABETES

Streptozotocin-induced hyperglycemia results in changes in the retinal pigmented layer characterized by increased thickness of the middle retinal layers, increased new vessel formation, reactive endothelium, dilated capillaries distended with either blood or serous fluid, acute inflammation composed of intravascular neutrophils, and neutrophils adhered to vessel walls and extravascularly at 4 weeks post-STZ treatment. In collaboration with board certified ophthalmologists (DACVO) and our expert team, CBI has enabled dozens of clients to reach their next clinical milestones.



A full validation of this model for your future research needs can be viewed here:

[Read STZ-Induced Hyperglycemia Model White Paper Here](#)

Douglas Crowder
(408) 738-9268
douglas_crowder@compbio.com

[Visit our website!](#)

Assembling expert professionals, developing premiere scientific facilities, and creating cutting edge management systems represents the underlying infrastructure that supports CBI and facilitates our clients' regulatory submissions.

www.compbio.com



[CONTACT US!](#)

STAY CONNECTED

View our profile on [LinkedIn](#)